Genetic Signatures Secures Decade-Long Danish Supply Deal for Gastrointestinal Testing

Long-Term Danish Contract Validates Pan-Enteric Platform

Genetic Signatures Limited (ASX:GSS) has secured a substantial supply agreement with Hvidovre Hospital, one of Denmark’s premier public health institutions, for its EasyScreen™ Pan-Enteric assay. The deal spans a decade, with an initial volume of 28,000 tests expected in the first year, growing at an estimated 3% annually. This contract is a milestone for Genetic Signatures’ push into the EMEA region, demonstrating international acceptance of its 3base® multiplex technology.

The agreement encompasses the supply of equipment, reagents, and consumables, with commercial orders slated to begin in September 2026 following installation and validation. Although pricing details remain confidential, the contract’s scale and duration underscore the assay’s perceived value in streamlining gastrointestinal pathogen detection.

Simplifying Complex Diagnostics with 3base® Technology

The EasyScreen™ Pan-Enteric assay consolidates what has traditionally required multiple tests, culturing, ELISA, and various PCR assays, into a single, fully automated workflow. It simultaneously detects 24 different gastrointestinal pathogens, including bacteria, viruses, and parasites, from one patient sample. This simplification reduces laboratory complexity, lowers infection-control risks, and improves patient management by shortening hospital stays and preventing ward closures.

Previous clinical validation in the United Kingdom has shown the assay’s tangible benefits: tripling diagnostic yield, reducing turnaround times, and enabling more targeted antibiotic use. These outcomes highlight the assay’s potential to deliver system-wide health economic advantages, from laboratory efficiency to hospital operations. The Danish contract follows a reshaped operations plan that aims to sharpen Genetic Signatures’ commercial focus and accelerate growth, adding weight to the company’s strategic direction.

Strategic Implications for European Expansion

John Buckles, Director of EMEA Operations, framed the Hvidovre contract as a critical endorsement of Genetic Signatures’ technology within a sophisticated healthcare market. CEO Maria Halasz emphasised the contract’s role in building momentum for broader European and global adoption. The deal’s timing aligns with recent leadership changes aimed at scaling the company’s footprint, including Halasz’s appointment earlier this year.

While the contract’s financial terms are undisclosed, the volume commitments and long duration suggest a meaningful revenue stream starting late 2026. The agreement also sets a precedent for future tenders in Europe, where demand for efficient, multiplex diagnostics is rising amid ongoing pressures on healthcare systems.

Looking Ahead to Market Adoption and Competitive Dynamics

Genetic Signatures now faces the task of converting this contract into sustained growth and leveraging its clinical validation to win further European hospital tenders. The company’s ability to scale manufacturing, maintain quality, and support customers through installation and validation will be critical. Additionally, monitoring uptake beyond initial volumes and any competitive responses from established diagnostic players will be key to assessing the broader impact of this agreement.